Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma

Haitz, Karyn; Khosravi, Hamed; Lin, Jennifer Y.; Menge, Tyler; Nambudiri, Vinod E.

doi:10.1016/j.jaad.2020.01.039

Cited by 27 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oncolytic viruses eradicate cancer cells by two major distinct mechanisms: oncolytic activity that directly lyses infected cells, and anti-cancer immune responses that are indirectly induced by virus infection of cancer cells. To date, none of the available oncolytic viruses, FDA-approved [ 33 ] or those under investigation [ 34 , 35 , 36 , 37 ], have been potent enough to eradicate all cancer cells in animal models or cancer patients. Enhancement of oncolytic activity is one of the main future directions in the field, however, off-target toxicity remains a big concern.…”

Section: Discussionmentioning

confidence: 99%

Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment

Yue

Yang

Yao

et al. 2021

Cancers

View full text Add to dashboard Cite

CA-125, encoded by the MUC16 gene, is highly expressed in most ovarian cancer cells and thus serves as a tumor marker for monitoring disease progression or treatment response in ovarian cancer patients. However, targeting MUC16/CA-125 for ovarian cancer treatment has not been successful to date. In the current study, we performed multiple steps of high-fidelity PCR and obtained a 5 kb DNA fragment upstream of the human MUC16 gene. Reporter assays indicate that this DNA fragment possesses transactivation activity in CA-125-high cancer cells, but not in CA-125-low cancer cells, indicating that the DNA fragment contains the transactivation region that controls specific expression of the MUC16 gene in ovarian cancer cells. We further refined the promoter and found a 1040 bp fragment with similar transcriptional activity and specificity. We used this refined MUC16 promoter to replace the E1A promoter in the adenovirus type 5 genome DNA, where E1A is an essential gene for adenovirus replication. We then generated a conditionally replicative oncolytic adenovirus (CRAd) that replicates in and lyses CA-125-high cancer cells, but not CA-125-low or -negative cancer cells. In vivo studies showed that intraperitoneal virus injection prolonged the survival of NSG mice inoculated intraperitoneally (ip) with selected ovarian cancer cell lines. Furthermore, the CRAd replicates in and lyses primary ovarian cancer cells, but not normal cells, collected from ovarian cancer patients. Collectively, these data indicate that targeting MUC16 transactivation utilizing CRAd is a feasible approach for ovarian cancer treatment that warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment

Yue

Yang

Yao

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…10 The first oncolytic virus registered by the FDA and EMA is talimogene laherparepvec, which is used in advanced melanoma and has shown efficacy on overall survival for patients with cutaneous metastases. 11 Available data show that the expected survival for stage IIIB melanoma patients treated according to standard treatments in the United States 9.4 years after diagnosis is approximately 45%. 12…”

Section: Discussionmentioning

confidence: 99%

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

Sorokins¹,

Tilgase²,

Olmane

et al. 2020

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia. A female patient was diagnosed with stage IIIB melanoma in December 2012, over 9.4 years ago. After the first excision and re-excision, the patient had several recurrences and disease progressions. After the patient had received surgical treatment in 2014, ECHO-7 virus oncolytic virotherapy was started. Since then, the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months. The patient has not received any other treatment than surgery and oncolytic virotherapy. No severe adverse events have been reported during virotherapy. The present case suggests that ECHO-7 virotherapy is an effective treatment of skin melanoma.

show abstract

“…The efficacy of T-VEC coupled with pembrolizumab treatment was evaluated as a phase Ib trial for the treatment of stage IIIB to IV unresectable melanoma. In this clinical trial, 21 patients received a dose of T-VEC (4 mL × 10 6 pfu/mL), up to a total dose of 4 mL × 10 8 pfu/mL every 2 weeks [ 137 , 138 ]. Intravenous administration of 200 mg of pembrolizumab was performed with subsequent delivery of T-VEC.…”

Section: Combination Therapies With Icismentioning

confidence: 99%

Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

Kim

Sang

Lee

et al. 2021

IJMS

View full text Add to dashboard Cite

Therapeutic cancer vaccines have become increasingly qualified for use in personalized cancer immunotherapy. A deeper understanding of tumor immunology and novel antigen delivery technologies has assisted in optimizing vaccine design. Therapeutic cancer vaccines aim to establish long-lasting immunological memory against tumor cells, thereby leading to effective tumor regression and minimizing non-specific or adverse events. However, due to several resistance mechanisms, significant challenges remain to be solved in order to achieve these goals. In this review, we describe our current understanding with respect to the use of the antigen repertoire in vaccine platform development. We also summarize various intrinsic and extrinsic resistance mechanisms behind the failure of cancer vaccine development in the past. Finally, we suggest a strategy that combines immune checkpoint inhibitors to enhance the efficacy of cancer vaccines.

show abstract

Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma

Cited by 27 publications

References 38 publications

Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment

Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

Contact Info

Product

Resources

About